FDA eases clozapine restrictions for pediatric schizophrenia; stigma persists

The FDA has reduced regulatory burdens on clozapine, a highly effective antipsychotic for treatment-resistant schizophrenia in children, but prescriber and patient fear of side effects continues to limit its use. The change removes some monitoring requirements, yet the drug remains underutilized due to lingering safety concerns. This matters because it could improve access to a critical treatment for a vulnerable pediatric population, though real-world uptake may remain slow.